RxDoctor Payments Data

Jason Fishel, MD

Family Medicine · Charlotte, NCNPI 1760877716

Payments from drug & device makers

$1,576in general payments, 2019–2025

Across 35 payments — averaging $45.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lundbeck LLC$125
  • Abbott$125
  • Johnson & Johnson$93
  • BD$30
  • GSK$16

What the payments were for

  • Speaking & faculty fees$302%
  • Food & beverage$1,54698%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk30$1,187
Lundbeck LLC1$125
Abbott1$125
Johnson & Johnson1$93
BD1$30
GSK1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,576 in reported general payments places this provider in the 75th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$37,786
Medicare patients
109
Services billed
419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide42$67,093
PercocetOxycodone Hcl/Acetaminophen12$51,462
OzempicSemaglutide31$40,647
JardianceEmpagliflozin22$37,825
TrulicityDulaglutide23$37,613
EliquisApixaban31$23,129
AdderallDextroamphetamine/Amphetamine11$20,214
JanuviaSitagliptin Phosphate17$15,757
SymbicortBudesonide/Formoterol Fumarate14$3,174
Esomeprazole Magnesium27$2,514
Omeprazole99$1,738
Rosuvastatin Calcium123$1,722
Gabapentin92$1,488
Atorvastatin Calcium173$1,422
Candesartan Cilexetil12$1,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,187$40,64731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →